It depends what you consider the market.Kaken basically had...

It depends what you consider the market.

Kaken basically had 200,000 new patients in the first year, I think BOT will have more.

Not only that. Every BOT patient that renews the script , effectively doubles the patient numbers, since most Japanese on average buy 1 script only. Most americans buy 2.

So although market penetration might oly be 2% or whatever.... if they renew 4 scripts on average.... that is the exquivalent of 4x market penetration in income.

Based on what happened in Japan, it is entirely feasable that the sales in year 1 will be around the 1 billion mark.
Take the same year 1 sales Kaken had, adjust for USA being 3 x the size, and adjust for the fact that USA on average renew 2 scripts where as Japan do not renew. That gives you 900,000 USD in sales ~ or about 1.3 to 1.4 Billion in AUS sales.

The first quarter report will be the first indication of where on that scale we are.